The 2024 MD Anderson Cancer Center/Baylor College of Medicine Hematology and Medical Oncology Board Review Materials

This program should be of interest to Physicians, Advanced Practice Providers, Nurses, and Advanced Practice Registered Nurses.

1. Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology;
2. Utilize current standards of care for patients with cancer, blood disorders and malignancies;
3. Demonstrate proficiency of knowledge in hematology and medical oncology;
4. Incorporate recent advances in management of hematologic and oncologic patients; and
5. Define molecular determinants of cancer risk and apply this knowledge in practice.

To view a full listing of the lecturers and their topics, please review the conference agenda below:

Conference Brochure

• Solid Tumors Session
• Malignant Hematology Session
• Classical (Benign) Hematology Session

Full List of Topics:

Monday, August 19, 2024

• Testicular Cancer
  Timothy Gilligan, MD
• Urothelial Cancer
  Arlene Siefker-Radtke, MD
• Renal Cell Carcinoma
  Eric Jonasch, MD
• Prostate Cancer
  Brad Carthon, MD
• Melanoma
  Rodabe Amaria, MD
• Q & A Panel Discussion
  Timothy Gilligan, MD; Arlene Siefker-Radtke, MD; Eric Jonasch, MD; Brad Carthon, MD; Rodabe Amaria, MD
• Pancreaticobiliary Cancers/Unknown Primary
  Robert Wolff, MD
• Gastroesophageal Cancers/Hepatocellular Carcinoma
  Harry Yoon, MD
• Colorectal Cancer: Biology and Adjuvant Therapy
  Scott Kopetz, MD, PhD
• Metastatic Colorectal Cancer and Anal Cancer
  A. Koneti Rao, MD, FACP
• Q & A Panel Discussion
  Robert Wolff, MD; Harry Yoon, MD; Scott Kopetz, MD, PhD; A. Koneti Rao, MD, FACP
• Solid Tumor Q & A – Session 1: Genitourinary Oncology/Gastrointestinal Oncology/ Melanoma
  Megan Dupuis, MD

Tuesday, August 20, 2024

• Pharmacology I: Chemotherapy
  Claire Mach, PharmD
• Pharmacology II: Targeted Therapy (ALK, EGFR, VEGR, HER2, HH, mTOR)
  Whitney Lewis, PharmD
• Pharmacology III: Targeted Therapy (CD20, CD30, CD33, Proteasome, BCR-ABL/KIT, FLT3, IDH1/2, CDK4/6, PI3K)
  Brian Primeaux, PharmD
• Pharmacology IV: Immunotherapy
  Claire Mach, PharmD
• Genetic Risk Factors
  Claudine Isaacs, MD
• Sarcoma
  Shreyaskumar Patel, MD
• Q & A Panel Discussion
  Claire Mach, PharmD; Whitney Lewis, PharmD; Brian Primeaux, PharmD; Claudine Isaacs, MD; Shreyaskumar Patel, MD
• Screening/Local Management of Breast Cancer
  Abenaa Brewster, MD
• Systemic Treatment of Primary Breast Cancer Including HER2 Positive Breast Disease
  Sharon Giordano, MD
• Treatment of Metastatic Breast Cancer Including HER2 Positive Breast Disease
  Mariana Chavez MacGregor, MD
• Special Issues in Breast Cancer
  Jennifer Litton, MD
• Q & A Panel Discussion
  Abenaa Brewster, MD; Sharon Giordano, MD; Mariana Chavez MacGregor, MD; Jennifer Litton, MD
• Solid Tumor Q & A – Session 2: Pharmacology/Genetic Risk Factors/Sarcoma/Breast Cancer
  Mark Lewis, MD

Wednesday, August 21, 2024

• Early Stage and Locally Advanced Non-Small Cell Lung Cancer
  Nasser Hanna, MD
• Metastatic Non-Small Cell Lung Cancer
  Nasser Hanna, MD
• Small Cell Lung Cancer
  Carl Gay, MD
• Head and Neck Cancer
  William N. William, Jr., MD
• Thyroid Cancer
  Mimi Hu, MD
• Q & A Panel Discussion
  Nasser Hanna, MD; Carl Gay, MD; William N. William, Jr., MD; Mimi Hu, MD
• ASH/ASCO Choosing Wisely Recommendations
  Ravin Garg, MD
• Neuro-Oncology
  Antonio Omuro, MD
• Cervical Cancer
  Alejandro Rauh Hain, MD
• Uterine Cancer
  TBD
• Ovarian Cancer and Unusual Ovarian Histologies
  TBD
• Q & A Panel Discussion
  Antonio Omuro, MD; Alejandro Rauh Hain, MD
• Solid Tumor Q & A – Session 3: Lung Cancer/Head Neck Cancer/Thyroid Cancer/Neuro-Onc/Gynecologic Oncology
  Ravin Garg, MD

Thursday, August 22, 2024

• Classification of Lymphoma
  Jeffrey Medeiros, MD
• Aggressive Non-Hodgkin Lymphoma
  Christopher Flowers, MD
• Indolent Non-Hodgkin Lymphoma
  Carla Casulo, MD
• Hodgkin Lymphoma
  Alison Moskowitz, MD
• Multiple Myeloma and Other Plasma Cell Dyscrasias
  S. Vincent Rajkumar, MD, PhD
• Q & A Panel Discussion
  Jeffrey Medeiros, MD; Christopher Flowers, MD; Carla Casulo, MD; Alison Moskowitz, MD; S. Vincent Rajkumar, MD, PhD
• Chronic Myeloid Leukemia
  Jorge Cortes, MD
• Myelodysplastic Syndrome
  Tapan Kadia, MD
• Infectious Complications in Cancer Patients
  Samuel Shelburne, MD, PhD
• Acute Lymphoblastic Leukemia
  Hagop Kantarjian, MD
• Q & A Panel Discussion
  Jorge Cortes, MD; Tapan Kadia, MD; Samuel Shelburne, MD, PhD; Hagop Kantarjian, MD
• Malignant Hematology Q & A Session
  Patrick Reville, MD

Friday, August 23, 2024

• Chronic Lymphocytic Leukemia and Hairy Cell Leukemia
  Susan O’Brien, MD
• Myeloproliferative Neoplasms
  Raajit Rampal, MD
• Acute Myeloid Leukemia
  Courtney DiNardo, MD
• Stem Cell Transplant Supportive Care
  Betty Hamilton, MD
• Q & A Panel Discussion
  Susan O’Brien, MD; Raajit Rampal, MD; Courtney DiNardo, MD; Betty Hamilton, MD
• Iron Deficiency and Hemochromatosis
  Matthew Heeney, MD
• Hematopoietic Growth Factors
  Martha Mims, MD, PhD
• Bone Marrow Failure
  Timothy Olson, MD, PhD
• Leukopenia and Leukocytosis
  Nancy Berliner, MD
• Hemolytic Anemias
  Gerald Soff, MD
• Q & A Panel Discussion
  Matthew Heeney, MD; Martha Mims, MD, PhD; Timothy Olson, MD, PhD; Nancy Berliner, MD; Gerald Soff, MD

Saturday, August 24, 2024

• Sickle Cell Anemias, Thalassemia, and Hemoglobinopathies
  Alice Ma, MD
• Issues in Transfusion Medicine
  Kerry O’Brien, MD
• Approach to Anemia
  Alice Ma, MD
• Disorders of Platelet Function
  A. Koneti Rao, MD, FACP
• Thrombocytopenias
  Alfred Lee, MD
• Q & A Panel Discussion
  Alice Ma, MD; Kerry O’Brien, MD; A. Koneti Rao, MD, FACP; Alfred Lee, MD
• Antithrombotic & Antiplatelet Therapy
  Bethany Samuelson, MD
• Normal Coagulation
  Kenneth Bauer, MD
• Coagulation Factor Deficiencies, Including von Willebrand’s Disease and Hemophilias
  Kenneth Bauer, MD
• Hypercoagulable States
  Stephan Moll, MD
• Q & A Panel Discussion
  Senthil Sukumar, MD; Bethany Samuelson, MD; Kenneth Bauer, MD; Stephan Moll, MD